Low cerebrospinal fluid sulfatide predicts progression of white matter lesions - The LADIS study

Dementia and Geriatric Cognitive Disorders

Volumn 34, Issue 1, 2012, Pages 61-67

  Jonsson, Michael ^a   Zetterberg, Henrik ^a   Rolstad, Sindre ^a   Edman, Ake ^a   Gouw, Alida A ^b   Bjerke, Maria ^a   Lind, Karin ^a   Blennow, Kaj ^a   Pantoni, Leonardo ^c   Inzitari, Domenico ^c   Wallin, Anders ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biomarkers; Cerebrospinal fluid; Leukoaraiosis; Myelin; Oligodendrocyte; Progression; Sulfatide

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN LIGHT SUBUNIT; SULFATIDE; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CEREBROSPINAL FLUID LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DISABILITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LEUKOARAIOSIS; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NEUROCHEMISTRY; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RATING SCALE; ROTTERDAM PROGRESSION SCALE; SULFATIDE CEREBROSPINAL FLUID LEVEL; THIN LAYER CHROMATOGRAPHY; WHITE MATTER LESION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; DEMENTIA, VASCULAR; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEUKOARAIOSIS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; NERVE DEGENERATION; NETHERLANDS; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; SOCIOECONOMIC FACTORS; SULFOGLYCOSPHINGOLIPIDS; TAU PROTEINS;

EID: 84865279982     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000341576     Document Type: Article

References (41)

1. Hachinski VC, Potter P, Merskey H: Leukoaraiosis. Arch Neurol 1987;44:21-23.
2. Wahlund LO, Barkhof F, Fazekas F, et al: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-1322. (Pubitemid 32530416)
3. Erkinjuntti T, Inzitari D, Pantoni L, et al: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-30. (Pubitemid 30479402)
4. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1:426-436. (Pubitemid 37159153)
5. Pantoni L: Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9:689-701.
6. Pantoni L, Basile AM, Pracucci G, et al: Impact of age-related cerebral white matter changes on the transition to disability - the LADIS study: rationale, design and methodology. Neuroepidemiology 2005;24:51-62. (Pubitemid 39664108)
7. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA: MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149: 351-356. (Pubitemid 17104996)
8. Inzitari D, Pracucci G, Poggesi A, et al: Changes in white matter as determinant of global functional decline in older independent outpatients: three-year follow-up of LADIS (Leukoaraiosis And DISability) study cohort. BMJ 2009;339:b2477.
9. Gouw AA, van der Flier WM, Fazekas F, et al: Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 2008;39:1414-1420.
10. Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr, et al: Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005;36:56-61. (Pubitemid 40054175)
11. Grinberg LT, Thal DR: Vascular pathology in the aged human brain. Acta Neuropathol 2010;119:277-290.
12. Pantoni L: Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 2002;13(suppl 2):7-10. (Pubitemid 34233902)
13. Rosenberg GA: Inflammation and white matter damage in vascular cognitive impairment. Stroke 2009;40:S20-S23.
14. Wallin A, Sjogren M, Edman A, Blennow K, Regland B: Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol 2000;44:229-235.
15. Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries CG, Svennerholm L: Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta Neurol Scand 1992;85:103-106.
16. Tullberg M, Mansson JE, Fredman P, et al: CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry 2000;69:74-81. (Pubitemid 30410418)
17. Tullberg M, Hultin L, Ekholm S, Mansson JE, Fredman P, Wikkelso C: White matter changes in normal pressure hydrocephalus and Binswanger disease: specificity, predictive value and correlations to axonal degeneration and demyelination. Acta Neurol Scand 2002;105:417-426. (Pubitemid 34620567)
18. Tarkowski E, Tullberg M, Fredman P, Wikkelso C: Correlation between intrathecal sulfatide and TNF-α levels in patients with vascular dementia. Dement Geriatr Cogn Disord 2003;15:207-211. (Pubitemid 36302377)
19. Wallin A, Sjogren M: Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Ageing Dev 2001;122:1937-1949. (Pubitemid 32925104)
20. Sjogren M, Blomberg M, Jonsson M, et al: Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001;66:510-516. (Pubitemid 33027419)
21. Jonsson M, Zetterberg H, van Straaten E, et al: Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol 2010;17: 377-382.
22. Bjerke M, Andreasson U, Rolstad S, et al: Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord 2009;28:348-356.
23. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9:179-186.
24. Zetterberg H, Andreasson U, Hansson O, et al: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 2008;65:1102-1107.
25. Olsson A, Vanderstichele H, Andreasen N, et al: Simultaneous measurement of β-amyloid1-42, total , and phosphorylated (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-345. (Pubitemid 40175803)
26. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-2018. (Pubitemid 26349676)
27. Davidsson P, Fredman P, Mansson JE, Svennerholm L: Determination of gangliosides and sulfatide in human cerebrospinal fluid with a microimmunoaffinity technique. Clin Chim Acta 1991;197:105-115.
28. Tibbling G, Link H, Ohman S: Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385-390. (Pubitemid 8387871)
29. Van Straaten EC, Fazekas F, Rostrup E, et al: Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke 2006;37: 836-840. (Pubitemid 43731918)
30. Prins ND, van Straaten EC, van Dijk EJ, et al: Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology 2004;62:1533-1539. (Pubitemid 38608191)
31. Achen CH: A Polychotomous Linear Probability Model. Berkeley, Political Methodology Society, 1991.
32. Berry WD: Understanding Regression Assumptions. Thousand Oaks, Sage Publications, 1993.
33. Blennow K: CSF biomarkers for mild cognitive impairment. J Intern Med 2004;256:224-234. (Pubitemid 39222991)
34. Tarvonen-Schroder S, Blennow K, Lekman A, Fredman P, Raiha I, Sourander L: Gangliosides and sulfatide in cerebrospinal fluid in leukoaraiosis. Dement Geriatr Cogn Disord 1997;8:174-179. (Pubitemid 27183223)
35. Franklin RJ, Kotter MR: The biology of CNS remyelination: the key to therapeutic advances. J Neurol 2008;255(suppl 1):19-25. (Pubitemid 351341869)
36. Bansal R, Winkler S, Bheddah S: Negative regulation of oligodendrocyte differentiation by galactosphingolipids. J Neurosci 1999;19: 7913-7924. (Pubitemid 30225789)
37. Duncan ID, Brower A, Kondo Y, Curlee JF Jr, Schultz RD: Extensive remyelination of the CNS leads to functional recovery. Proc Natl Acad Sci USA 2009;106:6832-6836.
38. Franklin RJ, Zhao C, Sim FJ: Ageing and CNS remyelination. Neuroreport 2002;13:923-928. (Pubitemid 34518210)
39. Armstrong RC: Growth factor regulation of remyelination: behind the growing interest in endogenous cell repair of the CNS. Future Neurol 2007;2:689-697. (Pubitemid 350111136)
40. Ropele S, Seewann A, Gouw AA, et al: Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion- weighted and magnetization transfer imaging: the LADIS (Leukoaraiosis and Disability in the Elderly) study. J Magn Reson Imaging 2009;29:268-274.
41. Schmidt R, Ropele S, Ferro J, et al: Diffusionweighted imaging and cognition in the leukoariosis and disability in the elderly study. Stroke 2010;41:e402-e408.